회사 개요
Annovis Bio, Inc. operates as a clinical stage drug platform company focused on the United States market, specifically developing therapeutic interventions for neurodegenerative conditions. The firm is situated within the Healthcare sector and the Biotechnology industry, a classification that signifies its reliance on extensive research and development to bring novel treatments to patients suffering from complex neurological disorders. In terms of scale, the company currently holds a market capitalization of $45.94M and employs a workforce of 7 individuals, reflecting a small-cap, early-stage operational footprint. The market cap figure of $45.94M indicates that the company is a micro-cap entity with limited public float and liquidity, while the absence of reported annual revenue underscores that the business is still in the investment phase where capital allocation is directed toward product development rather than commercial sales generation.
재무 건전성
The company reports no revenue over the trailing twelve-month period, while simultaneously posting a net income of $-28,854,196, which highlights a cost structure entirely consumed by operating expenses and R&D investments prior to any commercial revenue stream. EBITDA is listed as not available, further emphasizing that the firm has not yet achieved the cash flow levels necessary to calculate traditional enterprise value multiples based on earnings before interest, taxes, depreciation, and amortization. Free cash flow stands at $-15,183,042, indicating that the company is burning cash rapidly to fund its clinical trials and operational infrastructure, thereby limiting its current financial flexibility to self-funding without additional capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is typical for pre-revenue biotechnology firms but confirms that the company has not yet generated revenue to calculate profitability percentages. On the balance sheet, the company holds $19.53M in cash against $0 in debt, resulting in a debt-to-equity ratio that is not applicable due to the lack of equity or debt in the traditional sense for this calculation context. The current ratio is 5.80, a figure that suggests strong short-term liquidity relative to obligations, primarily driven by the significant cash reserve relative to current liabilities. Return on Equity is -220.6% and Return on Assets is -106.0%, metrics that reveal that management effectiveness is currently measured by the preservation of capital rather than the generation of positive returns on deployed assets.
밸류에이션 평가
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed at -1.50, a disparity that implies the market is valuing the company based on projected losses or a forward-looking narrative rather than historical earnings power. The price-to-book ratio stands at 2.61, indicating that the market values the company's equity at a premium of 2.61 times its book value, reflecting the intangible value of its clinical pipeline and intellectual property rather than tangible assets. Price-to-sales and EV/EBITDA metrics are not available, which prevents traditional valuation comparisons and suggests that investors must rely on clinical milestones and cash runway rather than standard multiple expansion logic. The stock has traded between a 52-week low of $1.11 and a 52-week high of $5.50, creating a wide trading range that reflects high volatility typical of small-cap biotechnology stocks. The beta value of 1.36 indicates that the stock price is 36% more volatile than the broader market, meaning that market fluctuations will be amplified when applied to this specific asset class.
Growth & Income
Revenue growth and earnings growth rates are both not available for the year-over-year period, as the company has not yet commercialized its lead product candidate Buntanetap to generate comparable historical financial data. Consequently, the earnings growth relative to revenue cannot be calculated, but the trajectory points toward a period of negative earnings growth until the transition from clinical development to commercial launch occurs. The company does not pay dividends, evidenced by a dividend yield of not available and a payout ratio of 0.0%, which means all available cash flow is being reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is standard for clinical stage biotechnology firms, where capital retention is essential to advance the lead product candidates through phase 2 and phase 3 trials for conditions such as Alzheimer's disease and Parkinson's disease.